Streetbeat News

Price Targets

CTV

Needham analyst Laura Martin has maintained a Buy rating on Innovid (NYSE:CTV) and increased the price target from $1.5 to $2.25.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 11:59 am

FUBO

Needham analyst Laura Martin has reiterated a Buy rating on FuboTV (NYSE:FUBO) and maintained a $4 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 11:57 am

IMRX

Needham analyst Ami Fadia has initiated coverage on Immuneering Corporation (NASDAQ:IMRX) with a Buy rating and set a price target of $20.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 11:55 am

ARE

JMP Securities analyst Aaron Hecht has maintained a Market Outperform rating on Alexandria Real Estate (NYSE:ARE) but has reduced the price target from $160 to $140.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 11:54 am

CHS

Telsey Advisory Group analyst Dana Telsey has reiterated a 'Market Perform' rating on Chico's FAS (NYSE:CHS) and maintained a price target of $7.6 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 11:52 am

LULU

Citigroup analyst Paul Lejuez has reaffirmed a Buy rating on Lululemon Athletica (NASDAQ:LULU) and increased the price target from $450 to $520.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 11:52 am

TXRH

Piper Sandler analyst Brian Mullan has downgraded Texas Roadhouse (TXRH) from Overweight to Neutral and set a price target of $110. This reflects a change in the analyst's outlook on the stock, suggesting a more cautious stance on its future performance.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 11:50 am

BNTX

JP Morgan analyst Jessica Fye has downgraded BioNTech (BNTX) from Neutral to Underweight and reduced the price target from $106 to $99.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 11:48 am

MKTW

UBS analyst Alex Kramm has downgraded Marketwise (NASDAQ:MKTW) from Buy to Neutral while increasing the price target from $3 to $3.5.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 11:43 am

IMGN

Jefferies analyst Kelly Shi downgraded Immunogen (NASDAQ:IMGN) from Buy to Hold and set a price target of $31. The downgrade reflects a more cautious stance on the stock's near-term performance.

Portfolio Pulse from Benzinga Newsdesk

December 01, 2023 | 11:40 am